Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AVL-101 for HPV16/18-positive cervical intraepithelial neoplasia grade 2/3
CTR20263922Phase 2Active
- Sponsor
- Anveto Biopharma
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AVL-101 in cervical intraepithelial neoplasia (CIN), sponsored by Anveto Biopharma. Started Oct 2026; status: active.
02
Drugs
AVL-101
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on CTR20263922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263922.